Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Fernando Rivera, Manuel Valladares, Salvador Gea & Noemí López-Martínez. (2017) Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of Medical Economics 20:6, pages 574-584.
Read now
Read now
Taehwan Park, Chang-ju Choi, Yeera Choi & Dong-Churl Suh. (2016) Cost-effectiveness of cetuximab for colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 667-677.
Read now
Read now
Louisa Lo, Dainik Patel, Amanda R Townsend & Timothy J Price. (2015) Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 11:12, pages 1907-1924.
Read now
Read now
Feng Wen, Yu Yang, Pengfei Zhang, Jian Zhang, Jing Zhou, Ruilei Tang, Hongdou Chen, Hanrui Zheng, Ping Fu & Qiu Li. (2015) Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study . Cancer Biology & Therapy 16:11, pages 1577-1584.
Read now
Read now
Kelly Lien, Scott Berry, Yoo-Joung Ko & Kelvin KW Chan. (2015) The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 81-100.
Read now
Read now
Articles from other publishers (21)
Takashi Morimoto, Kaori Fujito, Bumpei Yamasaki & Rei Goto. (2023) Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. Clinical Therapeutics 45:1, pages 41-54.
Crossref
Crossref
Reka E. Pataky, Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwatchai, Stuart Peacock, Riaz Alvi, Winson Y. Cheung, Craig C. Earle, Scott Gavura & Kelvin K. W. Chan. (2021) Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy & Practice 6:1, pages 238146832110210.
Crossref
Crossref
Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs & Maarten IJzerman. (2020) Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. PharmacoEconomics 38:7, pages 683-713.
Crossref
Crossref
Aaron P. Mitchell, Alan C. Kinlaw, Sharon Peacock-Hinton, Stacie B. Dusetzina, Hanna K. Sanoff & Jennifer L. Lund. (2020) Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. The Oncologist 25:1, pages 46-54.
Crossref
Crossref
Jiaqi Han, Desheng Xiao, Chongqing Tan, Xiaohui Zeng, Huabin Hu, Shan Zeng, Qin Jiang, Longjiang She, Linli Yao, Li Li, Lanhua Tang, Jian Ma, Jin Huang & Liangfang Shen. (2020) Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control 27:1, pages 107327482090227.
Crossref
Crossref
Yifan Xu, Joel W. Hay & Afsaneh Barzi. (2018) Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Mikyung Kelly Seo & John Cairns. (2018) Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLOS ONE 13:9, pages e0204496.
Crossref
Crossref
Veena Shankaran, Jesse D. Ortendahl, Anna G. Purdum, Bjorn Bolinder, Ayanna M. Anene, Gordon H. Sun & Tanya G.K. Bentley. (2018) Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology 41:1, pages 65-72.
Crossref
Crossref
Iakovos ToumazisMurat KurtArtemis ToumaziLoukia G. KaracostaChanghyun Kwon. (2017) Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy & Practice 2:2, pages 238146831772965.
Crossref
Crossref
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier & Martin Hoyle. (2017) The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment 21:38, pages 1-294.
Crossref
Crossref
M.D. Franken, E.M. van Rooijen, A.M. May, H. Koffijberg, H. van Tinteren, L. Mol, A.J. ten Tije, G.J. Creemers, A.M.T. van der Velden, B.C. Tanis, C.A. Uyl-de Groot, C.J.A. Punt, M. Koopman & M.G.H. van Oijen. (2017) Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. European Journal of Cancer 75, pages 204-212.
Crossref
Crossref
Shelby D. Reed, Eric Faulkner & David L. Veenstra. 2017. Genomic and Precision Medicine. Genomic and Precision Medicine
327
342
.
C E Koh, T Badgery-Parker, G Salkeld, J M Young, A G Heriot & M J Solomon. (2016) Cost-effectiveness of pelvic exenteration for locally advanced malignancy. British Journal of Surgery 103:11, pages 1548-1556.
Crossref
Crossref
Christopher N. Graham, Gregory A. Maglinte, Lee S. Schwartzberg, Timothy J. Price, Hediyyih N. Knox, Guy Hechmati, Jonas Hjelmgren, Beth Barber & Marwan G. Fakih. (2016) Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics 38:6, pages 1376-1391.
Crossref
Crossref
Shweta Jain & Veena Shankaran. (2016) The Economics of Personalized Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 12:3, pages 123-129.
Crossref
Crossref
Mira D Franken, Elisabeth M van Rooijen, Carin A Uyl-de Groot, Martijn GH van Oijen & Miriam Koopman. (2016) Cost–effectiveness in colorectal cancer: challenges on quality and comparability. Colorectal Cancer 5:1, pages 21-31.
Crossref
Crossref
Veena Shankaran. (2015) Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology 16:8.
Crossref
Crossref
Bruno KovicFeng Xie. (2015) Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology 33:20, pages 2296-2302.
Crossref
Crossref
Daniel A. GoldsteinQiushi ChenTurgay AyerDavid H. HowardJoseph LipscombBassel F. El-RayesChristopher R. Flowers. (2015) First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis. Journal of Clinical Oncology 33:10, pages 1112-1118.
Crossref
Crossref
Christopher N. Graham, Guy Hechmati, Jonas Hjelmgren, Frédérique de Liège, Julie Lanier, Hediyyih Knox & Beth Barber. (2014) Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer 50:16, pages 2791-2801.
Crossref
Crossref
Vijaya R Bhatt. (2014) Targeted therapy in metastatic colon cancer. Future Oncology 10:5, pages 707-711.
Crossref
Crossref